A Tetravalent Peptide That Binds to the RANK-binding Region of TRAF6 Via a Multivalent Interaction Efficiently Inhibits Osteoclast Differentiation
Overview
Authors
Affiliations
Inhibition of osteoclast differentiation is a promising approach for the treatment of osteoporosis and rheumatoid arthritis. Receptor activator of nuclear factor kappa B (NF-κB) (RANK), which is an essential molecule for osteoclast differentiation, interacts with tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) to transduce downstream signals. Both RANK and TRAF6 have homo-trimeric structures, forming a multivalent interaction between the Pro-X-Glu-X-X-(aromatic/acidic) motif of RANK and the C-terminal domain of TRAF6 (TRAF-C), that markedly increases the binding affinity. Here, we designed a tetravalent peptide, RANK-tet, containing the TRAF-C-binding motif of RANK and found that RANK-tet binds to TRAF-C with high affinity. In contrast, a monomeric form of RANK-tet (RANK-mono) with the same TRAF-C-binding motif did not bind to TRAF-C, clearly indicating the multivalent interaction is strictly required for the high-affinity binding to TRAF-C. RANK-tet did not bind to a series of TRAF-C-mutants with an amino acid substitution in the RANK-binding region, indicating that RANK-tet specifically targets the RANK-binding region of TRAF-C. A cell-permeable form of RANK-tet that has poly-Arg residues at each C-terminal of the TRAF-C-binding motif efficiently inhibited the RANK ligand (RANKL)-induced differentiation of bone marrow cells to osteoclasts. Thus, this compound can be an effective anti-osteoclastogenic agent.
Butyrate: a bridge between intestinal flora and rheumatoid arthritis.
Cao Y, Chen J, Xiao J, Hong Y, Xu K, Zhu Y Front Immunol. 2024; 15:1475529.
PMID: 39478858 PMC: 11521846. DOI: 10.3389/fimmu.2024.1475529.
Zheng H, Liu Y, Deng Y, Li Y, Liu S, Yang Y Mol Med. 2024; 30(1):20.
PMID: 38310228 PMC: 10838448. DOI: 10.1186/s10020-024-00788-w.